Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with strong phase II data showing 17.3 months median OS and improved tolerability. The drug's unique mechanism addresses prior MEK inhibitor limitations and supports future combination strategies with RAS inhibitors.B…
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with phase II data showing a median OS of 17.3 months and strong tolerability. The drug's unique mechanism and reduced toxicity differentiate it from earlier MEK inhibitors, and future strategies include synergistic c…